hrp0082p3-d1-706 | Diabetes | ESPE2014

Congenital Hyperinsulinism Linked to INS-R Mutation: Case Report

Vitaliti Marcello , Maggio Maria Cristina , Vitaliti Giuliana , Grasso Valeria , Ciofalo Amalia , Rinaudo Grazia , Tranchina Elisa , Costantino Giuseppina , Corsello Giovanni , Barbetti Fabrizio

Background: Leprechaunism, also known as Donohue syndrome, is due to a severe congenital insulin-resistance, with prenatal and neonatal growth retardation, typical dysmorphic features, glycaemic dysregulation with hyperinsulinism and hyperandrogenism.Objective and hypotheses: These patients have a poor prognosis with death in the first year of life.Method: We report the case of a newborn (35.4 weeks) with severe fetal growth restri...

hrp0089p2-p254 | Growth & Syndromes P2 | ESPE2018

Burden and Impacts of Daily Recombinant Human Growth Hormone (r-hGH) Injections in Growth Hormone Deficient (GHD) Paediatric Patients

Loftus Jane , Pleil Andreas , Lamoureux Roger , Turner-Bowker Diane , Yaworsky Andrew , Kelly Masami , Love Emily , McNamara Michelle , Palladino Andrew

Background: Daily r-hGH injection has been safely and effectively used in paediatric patients with GHD for more than 30 years. However, little information is available describing the burden and life impacts experienced by paediatric patients related to daily r-hGH injections.Objective: To identify the burden and impacts of a daily r-hGH injection regimen on the lives of paediatric GHD patients.Methods: A retrospective meta-analysis...

hrp0092p3-127 | Fat, Metabolism and Obesity | ESPE2019

Rosuvastatain Therapy in Children with Heterozygous Familial Hypercholesterolemia, Efficacy, and Security of Low Régimen of Therapy

Awadalla Shokery

Introduction: Heterozygous familial hypercholesterolemia is as frequent as 1: 200-500, and the mortality risk is four times more than unaffected children.Nutritional therapy in addition to physical activity can help but is not enough to avoid later morbidity and mortality. Stations have shown efficacy in children, but we do not have enough data for long term safety.Aim: to compare tow regimens of therapy using rosuvastat...

hrp0092lb-25 | Late Breaking Posters | ESPE2019

Low Trabecular Bone Score in Children with Inflammatory Bowel Diseases

Levy Shraga Yael , Megnazi Ophir , Modan-Moses Dalit , Tripto-Shkolnik Liana , Gruber Noah , Haberman Yael , Shouval Dror , Weiss Batia

Background: Trabecular bone score (TBS) is an emerging technology to assess bone microarchitecture of the lumbar spine. In adults, this score has been shown to be a significant predictor for osteoporotic fractures, independently of major clinical risk factors and bone mineral density (BMD), and is a recommended tool in the evaluation and management of osteoporosis, especially secondary osteoporosis. To date, only few studies evaluated TBS in the pediatric popu...

hrp0089p1-p158 | GH & IGFs P1 | ESPE2018

Patients and Caregivers Perspectives on a Mobile App that Tracks Adherence and Outcomes in Children with Growth Disorders Treated with Recombinant Human Growth Hormone (r-hGH)

McNally Mark , Long Frank , Poskitt Henry , Cancela Jorge , Koledova Ekaterina , Castro Javier Sanchez

Healthcare professionals (HCPs) receive adherence information on patient Saizen® recombinant human growth hormone (r-hGH) treatment via data wirelessly transferred from the easypodTM electromechanical delivery device to the web-based eHealth platform easypodTM connect. In order to empower patients and caregivers with this information and to provide educational tools, the growlinkTM mobile app is being ...

hrp0086rfc14.5 | Growth : Mechanisms | ESPE2016

Gene Expression Profiling of Children with GH Deficiency (GHD) Prior to Treatment with Recombinant Human Growth Hormone (r-hGH) is Associated with Growth Response Over Five Years of Therapy

Stevens Adam , Murray Philip , Koledova Ekaterina , Chatelain Pierre , Clayton Peter

Background: The relationship of pre-treatment gene expression (GE) to long-term growth response in GHD is unknown. Prediction of long-term response to r-hGH therapy would allow better decision making about start and maintenance doses and hence cost:benefit.Objective and hypotheses: To assess the relationship of baseline GE to response to r-hGH over 5 years of therapy in GHD children.Method: Pre-pubertal children with GHD (n</em...

hrp0097p1-99 | GH and IGFs | ESPE2023

Clinicians’ perceptions on ease of use and usefulness of Aluetta® Smartdot™ and comprehensive digital health ecosystem in Italy to support patients receiving r-hGH treatment

Felicia Faienza Maria , Vergani Edoardo , Di Mase Raffaella , Frasca Francesco , Giavoli Claudia , Klain Antonella , Laura Iezzi Maria , Aversa Antonio , Koledova Ekaterina , Rivera Romero Octavio

Background: Aluetta® Smartdot™ (Merck Healthcare KGaA, Darmstadt, Germany) is first of its kind digitally connected smart injection pen device for recombinant-human growth hormone (r-hGH) administration. Aluetta® pen with Smartdot™ knob attachment integrated with Growzen™ digital ecosystem enables healthcare professionals (HCPs) to remotely monitor adherence and achieve optimal clinical outcomes for patients....

hrp0095p1-568 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

Endocrine care for gender incongruent children and adolescents in The Czech Republic between 2011-2020

Neumann David , Snajderova Marta , Fifkova Hana , Weiss Petr , Zapletalova Jirina

Background: Gender incongruence (GI) is a topic of interest with major impacts on both the individual and society. In recent years, the small group of gender non-conforming children with an early GI history that persists through adolescence has been accompanied by a substantial rise in the proportion of adolescents reporting their gender doubts. The onset of gender dysphoria in this group is rapid. In the Czech Republic, multidisciplinary teams strive for high...

hrp0082p2-d2-335 | Diabetes (1) | ESPE2014

Insulin Therapy via Tubeless Patch Pump: Really an Alternative?

Boettcher Claudia , Schaefer Maike , Weiss Lucia , Wudy Stefan A

Background: For a few years now tubeless disposable patch pumps are available for insulin therapy.Objective and hypotheses: Alarmed by initially non explainable beginning metabolic decompensation of two children with type 1 diabetes during their hospital stay for the initial therapy adjustment with patch pumps and alarmed by patients’ reports of frequent premature pump changes and alarms, we decided to scrutinize the patch pumps under laboratory con...